Development and Commercialization of a Product Sample Clauses

Development and Commercialization of a Product. Upon completion of the Research Term and subject to the terms of the [***], following the successful identification of Lead Compounds as a result of the work conducted under the Research Plan, Icagen shall use Commercially Reasonable Efforts to develop a Lead Compound and, if appropriate under its sole discretion, clinically Develop and Commercialize a Product in the Field in the United States and in a Major European Market.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Development and Commercialization of a Product. Following the completion of the Research Program, Company shall, at its own (as compared to LLS’s) expense, use Commercially Reasonable Efforts to develop and, following receipt of Regulatory Approval in the applicable Major Market, to commercialize at least one (1) Product in the Field in each of the Major Markets.
Sample 1Sample 2
Development and Commercialization of a Product. Following the completion of the work set forth in the Research Plan relating to the Research Project, EPIX shall, at its own Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Exchange Act; [*] denotes omissions. expense, use Commercially Reasonable Efforts to develop, commercialize and bring at least one (1) Product in the Field identified in the Research Project to market. In connection therewith, EPIX shall use Commercially Reasonable Efforts: (i) to conduct all additional clinical trials required for Regulatory Approval, (ii) to file all required Registrations, (iii) to conduct any required post-marketing clinical studies, and (iii) to take all necessary or advisable actions in connection with the manufacturing, marketing, promotion, sales and distribution of a Product in the Field.
Sample 1
Development and Commercialization of a Product. Following the Research Termination Date, PTI shall use Commercially Reasonable Efforts to develop and commercialize a Product in the Field in the United States or in one or more countries of the European Union.
Sample 1
Development and Commercialization of a Product. Cxxxxx shall use Commercially Reasonable Efforts to develop and commercialize the Product in the United States and in one of the other Major Markets; provided however that nothing contained herein shall require Cxxxxx to initiate any other clinical trials (other than the Phase 2 Clinical Trial described herein) for the Product in the Field.
Sample 1
Development and Commercialization of a Product. 23 9.1 DEVELOPMENT AND COMMERCIALIZATION OF A PRODUCT. 23 9.2 COMMERCIALIZATION OF A PRODUCT. 23 9.3 ROYALTIES. 24 9.4 SALES REPORTS. 25 10. CONFIDENTIALITY. 26 10.1 CONFIDENTIALITY OBLIGATIONS. 26 10.2 EXCEPTIONS TO NON-DISCLOSURE OBLIGATION. 26 11. DISPUTE RESOLUTION. 27 11.1 PROCEDURES MANDATORY. 27 11.2 NEGOTIATION. 27 11.3 MEETING OF SENIOR MANAGEMENT. 27 11.4 FURTHER PROCEEDINGS: 28 11.5 ARBITRATION. 28 11.6 PRESERVATION OF RIGHTS PENDING RESOLUTION. 28 11.7 STATUTE OF LIMITATIONS. 29 11.8 FAILURE TO COMPLY WITH DISPUTE RESOLUTION PROCESS. 29 12. TERM AND TERMINATION; INTERRUPTION. 29 12.1 TERM. 29 12.2 TERMINATION FOR BREACH. 29 12.3 TERMINATION BY AFFIMED OR LLS. 30 12.4 INTERRUPTION. 30 12.5 SURVIVAL. 31 13. INDEMNIFICATION. 31 13.1 INDEMNIFICATION BY AFFIMED. 31 13.2 INDEMNIFICATION BY LLS. 32 13.3 INDEMNIFICATION PROCEDURES. 32 13.4 INSURANCE. 33 13.5 LIMITATION ON LIABILITY. 33 14. MISCELLANEOUS PROVISIONS. 34 14.1 RELATIONSHIP OF PARTIES. 34 14.2 GOVERNING LAW. 34 14.3 COUNTERPARTS. 34 14.4 BINDING EFFECT. 34 14.5 ASSIGNMENT AND SUBCONTRACTING. 34 14.6 ENTIRE AGREEMENT; AMENDMENT AND WAIVER. 34 14.7 NOTICE. 35 14.8 SEVERABILITY. 36 14.9 HEADINGS. 36 14.10 CONSTRUCTION OF THIS AGREEMENT. 36 14.11 FURTHER ASSURANCES. 36 14.12 FORCE MAJEURE. 36 Exhibit A – Budget Exhibit B – Compound Exhibit C – Milestones and Payments Exhibit D – AFM13 Proposal Exhibit E – Report Schedule 0000 Xxxxxxxxxx Xxxxxx, Xxxxx 000 Xxxxx Xxxxxx, XX 00000 XXX xxx.xxx.xxx Im Xxxxxxxxxxx Xxxx 000 69120 Heidelberg, Germany xxx.xxxxxxx.xxx RESEARCH FUNDING AGREEMENT This Agreement (the “Agreement”) is made as of August 26th, 2013 (the “Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 0000 Xxxxxxxxxx Xxxxxx, Xxxxx Xxxxxx, Xxx Xxxx 00000, Xxxxxx Xxxxxx xx Xxxxxxx (“LLS”) and Affimed Therapeutics AG, a German limited liability company with its principal place of business at Xx Xxxxxxxxxxx Xxxx 000, 69120 Heidelberg, Germany (“Affimed”). LLS and Affimed are sometimes hereinafter referred to individually as the “Party” and together as the “Parties”.
Sample 1
Development and Commercialization of a Product. Following the completion of the AFM13 Development Program, Affimed intends, at its own expense, to develop, commercialize and bring at least one (1) Product in the Field to First Commercial Sale, including, without limitation, by conducting clinical trials, filing applications for Regulatory Approval, and taking necessary or advisable actions in connection with the manufacturing, marketing, promotion, sales and distribution of the Product in the Field.
Sample 1
AutoNDA by SimpleDocs

Related to Development and Commercialization of a Product

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

Time is Money Join Law Insider Premium to draft better contracts faster.